An analysis of data from the British biologics registry found that the risk of lymphoma among patients with rheumatoid arthritis (RA) was not increased if they were treated with tumor necrosis factor (TNF) inhibitors. The study also found was no increased risk for the individual TNF inhibitors adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). People with RA have an increased risk of lymphoma, and there have been concerns about a further increase with TNF inhibitors, which is why these drugs carry a black box warning citing risks of lymphoma. The study authors called for more follow-up to see if the risk is altered by longer, cumulative exposure to anti-TNFs.
- News & Features